Viewing Study NCT03124368

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:27 PM
Ignite Modification Date: 2026-02-03 @ 8:10 PM
Study NCT ID: NCT03124368
Status: COMPLETED
Last Update Posted: 2021-11-04
First Post: 2017-04-12
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Sponsor: Alexion Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None C3 Glomerulonephritis View
None Dense Deposit Disease View
None C3 Glomerulopathy View
None Immune Complex Mediated Membranoproliferative Glomerulonephritis View
None Membranoproliferative Glomerulonephritis Types I, II, and III View
Keywords:

Keywords

Keyword Brief Keyword Text View
None factor D View
None FD View
None alternative pathway View
None complement mediated disease View
None idiopathic MPGN View
None MPGN Type I View
None MPGN Type II View
None MPGN Type III View
None Primary MPGN View
None MCGN View
None Mesangiocapillary Glomerulonephritis View
None C3 Glomerulopathy View
None C3G View
None Membranoproliferative Glomerulonephritis View
None C3GN View
None Dense Deposit Disease View
None DDD View